YD Pharmaceuticals

YD PharmaceuticalsYD Pharmaceuticals
YP

YD Pharmaceuticals

YD Pharmaceuticals is a Portuguese medical cannabis producer focused on high-quality cultivation and product development.

2022InactivePorto, Portugal

About

YD Pharmaceuticals is a company dedicated to the cultivation and production of medical cannabis in Portugal. They aim to provide high-quality cannabis products for therapeutic use, adhering to strict regulatory standards and focusing on innovation in their growing and processing methods.
Frequently asked

What does YD Pharmaceuticals do?

YD Pharmaceuticals is a company dedicated to the cultivation and production of medical cannabis in Portugal. They aim to provide high-quality cannabis products for therapeutic use, adhering to strict regulatory standards and focusing on innovation in their growing and processing methods.

Where is YD Pharmaceuticals headquartered?

YD Pharmaceuticals is headquartered in Porto, Portugal.

When was YD Pharmaceuticals founded?

YD Pharmaceuticals was founded in 2022.

What industry does YD Pharmaceuticals operate in?

YD Pharmaceuticals operates in Biotech, MedTech, HealthTech, Drug Discovery, Cannabis, Medical Cannabis.

What is YD Pharmaceuticals's current status?

YD Pharmaceuticals's current operating status is: Inactive.

New entrants in Biotech
Last 90 days
37
New entrants
12.3
Per month
2.9
Per week

An entrant is a company tagged Biotech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 8 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.

Scores
Measured, not editorial
Agent Readiness
22/100

How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.

Star ratings come from visitors, one per person per profile, and are shown exactly as given: we do not weight, curate or filter them. Reviews are published in full alongside the rating that accompanied them.

Comments

No comments yet. Be the first to share your take.